ClinicalTrials.gg
CompletedNCT07611058TETHERICUpdated May 28, 2026

Inflammatory Response in Children Suffering From Tethered Cord

An interventional study of CSF sampling during surgery in Tethered Spinal Cord, Including Thickened Filum, Lipomas, Myelomeningocele and Meningocele, sponsored by University Hospital, Lille. Completed at 1 site in France. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by University Hospital, Lille · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
Up to 17 Years
Sex
All
01

Study summary

Embryologic phenomenons that lead to dysraphisms are known, but pathophysiology remains questioned. It is supposed not to be a simple mechanistic dysfunction, and other biological phenomenons are implied in spinal cord damaging. Two main hypothesis are that manual deformation of the cells and mitochondrial membranes lead to energy deficiency and blood flow changes. On the other hand, considering traumatic spinal cord injuries (SCI), inflammation has been shown to have dramatic effects on spinal cord function and physiology. Indeed, all essays about SCI have demonstrated that the initial trauma leads to mechanical injury to cells, accompanied by damages of microvasculature, initiation of pro-apoptotic signaling and ischemia. Therefore, we could imagine that similar inflammatory processes can be implied in stretched spinal cord. In our review of literature, we found few papers highlighting the question of inflammation and CSF sampling.

02

Conditions studied

  • Tethered Spinal Cord, Including Thickened Filum, Lipomas, Myelomeningocele and Meningocele

Keywords

  • Tethered spinal cord
  • pediatric neurosurgery
  • inflammation
  • procteomics
03

In context

Lipoma

22 studies on the registry are indexed under Lipoma; 6 are open to participants now.

This study's enrollment of 32 is close to the median of 30 across 17 interventional studies indexed under Lipoma.

Browse Lipoma studies →

Lead sponsor

University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants and children under 18 years of age
  • Carriers of an attached marrow: lipomatous fiilum, meningocele, myelomeningocele, myelolipoma,
  • Consent of the child's parents,
  • Socially insured patient,
  • Patient willing to comply with all study procedures and duration,

Exclusion criteria

Exclusion Criteria:

  • Patients over 18 years of age,
  • Chronic inflammatory disease,
  • Ongoing anti-inflammatory treatments,
  • No parental consent,
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    all patients who are to undergo surgery for tethered spinal cord

    Experimental group: all patients who are to undergo surgery for tethered spinal cord, including thickened filum, lipomas, myelomeningocele and meningocele

    Procedure: CSF sampling during surgery

Interventions

  • ProcedureCSF sampling during surgery

    Proteomic studies will be led on the CSF samples, to identify inflammatory peptides and cells. The proteomic study will be correlated to clinical pre and post-operative data.

06

What researchers measure

Primary outcomes

  1. To describe the markers of chronic inflammation present in CSF collected at the beginning of surgery in children with attached low marrow.

    Proportion of patients with the presence of at least one marker of inflammation present in CSF collected at the beginning of surgery.

    Time frame: at the beginning of surgery

Secondary outcomes

  1. Proportion of patients with the presence of at least one marker of inflammation present in the CSF collected at the end of surgery.

    Time frame: at the end of surgery

  2. Proportion of patients with the presence of at least one marker of inflammation present in the CSF collected at the beginning of surgery and the proportion of patients with the presence of at least one marker of inflammation at the end of surgery

    Time frame: at the end of surgery

  3. The clinical outcome assessed by the NEM score in postoperative patients, immediately after surgery,3 months after surgery and 6 months after will be evaluated by the clinician in charge of the patient.

    Time frame: Immediately after surgery, 3 months after surgery and 6 months after surgery.

  4. The NEM score measured preoperatively and immediately postoperatively

    Time frame: Just before and immediately after surgery.

  5. The postoperative NEM score (immediately after surgery, 4 months after surgery and 18 months after) between patients with at least one of the inflammatory markers present and patients without inflammatory markers.

    Time frame: Immediately after surgery, 3 months after surgery and 6 months after surgery

07

Study locations

1 site
  • chu de Lille
    Lille, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Jan 2026, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2023
First posted
May 28, 2026
StartActual
May 16, 2024
Primary completionActual
Jan 5, 2026
CompletionActual
Jan 5, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07611058
Responsible party
Sponsor
First posted
May 28, 2026
Start date
May 16, 2024
Primary completion
Jan 5, 2026
Completion
Jan 5, 2026
Last update
May 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion